Cepheid is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company’s solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases, virology and cancer.
Randox Biosciences facilitates molecular diagnostic testing at the point of care with Vivalytic, a fully automated platform capable of both hi-plex and lo-plex testing. Vivalytic is powered by patented Randox Biochip Technology, enabling multiple results from one patient sample. A variety of tests including a 45 minute SARS-CoV-2 test and a10-plex STI test are available on Vivalytic.
Vivalytic is a lightweight device suitable for both laboratory and non-laboratory settings. The full molecular workflow is performed within the platform, including nucleic acid extraction, PCR, amplification and detection. No peripherals are required making Vivalytic a space-saving and hygienic solution.
The misuse and overuse of antibiotics has impacted their effectiveness globally. Diagnostics that detect infection and genetic markers for antibiotic resistance in a single test enable you to implement Resistance Guided Therapy (RGT). Utilising an RGT approach is clinically demonstrated to improve patient cure rates and is recommended by international bodies as the preferred method of treatment for infections such as Mycoplasma genitalium (Mgen) or gonorrhoea.
Visit the SpeeDx booth & learn how we can help you improve patient outcomes for Mgen, gonorrhoea, Herpes simplex virus (HSV-1&-2), Varicella zoster virus (VZV) & Treponema pallidum (Syphilis).
With a sustainable development over the past 65 years, Antibiotice is now the most prominent Romanian manufacturer of generic anti-infective drugs and the leading producer of ointments, suppositories and sterile powders for injection in terms of quantities.
Antibiotice’s portfolio includes 160 products of 12 different therapeutic classes, and its current growth strategy focuses on medicinal products of the following therapeutic areas: cardiovascular system, anti-infectives, nervous system, alimentary tract and dermatologicals.
The quality of the company’s products is confirmed by the GMP certificates for the eight manufacturing lines, the Certificate of Suitability to the monographs of the European Pharmacopoeia for the active pharmaceutical ingredient (API) Nystatin, as well as the FDA approval for the production of both the Nystatin API and the sterile powders for injection. Moreover, for the last 5 years, Antibiotice has been the number one worldwide manufacturer of Nystatin and in 2016, the same active ingredient became the USP international reference standard.
The growth of the international business operations led to the opening of representative offices in Vietnam, Republic of Moldova, Ukraine and Serbia and the creation of strategic partnerships in over 70 countries in all the continents of the world.
Fondatǎ în 1908 în Danemarca, LEO Pharma, deţinutǎ în prezent de Fundaţia LEO, este o companie farmaceuticǎ care a dedicat zeci de ani de cercetare şi dezvoltare pentru livrarea de produse celor care suferǎ de afecţiuni cutanate, oferind soluţii terapeutice pentru pacienţi din peste 130 de ţǎri şi având peste 5500 de angajaţi.
Compania LEO Pharma a sǎrbǎtorit în 2019, 20 de ani de activitate în România.
Misiunea noastrǎ este de a ajuta oamenii sǎ aibǎ o piele sǎnǎtoasǎ, iar pentru aceasta rǎmânem fideli ideii de a deveni partenerul preferat în asistenţa dermatologicǎ.
Sanofi Genzyme is Sanofi's specialized healthcare division, operating in 4 therapeutic areas: rare diseases, multiple sclerosis, oncology and immunology. A pioneering company in biotechnology, Sanofi Genzyme focuses on developing innovative therapies for debilitating conditions that are often difficult to diagnose and treat, giving hope to patients and their families. To identify and respond to complex health needs, Sanofi Genzyme has developed close relationships with medical communities and patient associations in a joint effort to facilitate access to early diagnosis and treatment for the effective management of these serious diseases.
Novartis is a global leader in immunology and dermatology. We are transforming the lives of people living with immunologic diseases, focusing on specialty dermatology, rheumatology, autoinflammatory, transplant, and specialty liver diseases where there remain high unmet medical needs.
Our focus on dermatology is on helping patients with moderate-to-severe skin diseases, including psoriasis and chronic spontaneous urticaria, which can significantly impact their quality of life.